louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06365372: Circulating MrgD in Pulmonary Hypertension
Official title: Circulating MrgD Change in Patients With Pulmonary Hypertension
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Pulmonary Hypertension
Lead sponsor: Qilu Hospital of Shandong University
Sponsor class: OTHER
First posted: 2024-04-15
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with pulmonary hypertension and control subjects

Brief summary: The aim of the study is to observe the change of the circulating MrgD level in patients with pulmonary hypertension compared with subjects without pulmonary hypertension.


Eligibility criteria: Inclusion criteria for patients with pulmonary hypertension：

1. Male or female aged ≥18 years
2. Right heart catheterisation to check the mean pulmonary artery pressure (mPAP) ≥25mmHg
3. The patient is willing and able to provide written informed consent.

Exclusion criteria for patients with pulmonary hypertension：

1. Age less than 18 years old
2. Mean pulmonary artery pressure (mPAP) \<25mmHg
3. Unable to provide informed written consent for participation in the study
4. Renal insufficiency
5. Liver insufficiency
6. Malignant tumor
7. Active infection
8. Pregnancy

Inclusion criteria for control subjects：

1. Male or female aged ≥18 years
2. No evidence of pulmonary hypertension on echocardiography or mean pulmonary artery pressure (mPAP) \< 25 mmHg on right heart catheterization, and no evidence of clinically relevant heart disease
3. No evidence of clinically relevant pulmonary disease

Exclusion criteria for control subjects：

1. Age less than 18 years old
2. Mean pulmonary artery pressure (mPAP) ≥25mmHg
3. Unable to provide informed written consent for participation in the study
4. Symptoms of heart failure or clinically relevant lung disease
5. Renal insufficiency
6. Liver insufficiency
7. Malignant tumor
8. Active infection
9. Pregnancy

Primary outcomes:
measure: Circulating MrgD level
timeFrame: From 2022 to 2024
Secondary outcomes:
Other outcomes:
Locations:
city: Jinan
country: China
facility: Qilu Hospital of Shandong University
state: Shandong
Study officials:
References:
Clinical trial NCT01131572: N-acetylcysteine in Bulimia Nervosa
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
PHASE3
Conditions: NAC
Lead sponsor: Lindner Center of HOPE
Sponsor class: OTHER
First posted: 2010-05-27
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study tests NAC in the treatment of Bulimia Nervosa.


Eligibility criteria: Inclusion Criteria:

* Bulimia Nervosa
* 18-65 years of age

Primary outcomes:
measure: Binge-purge episodes
timeFrame: per week
Secondary outcomes:
Other outcomes:
Locations:
city: Mason
country: United States
facility: Lindner Center of HOPE
state: Ohio
Study officials:
References:
citation: Guerdjikova AI, Blom TJ, Mori N, McElroy SL. N-acetylcysteine in bulimia nervosa--open-label trial. Eat Behav. 2013 Jan;14(1):87-9. doi: 10.1016/j.eatbeh.2012.11.001. Epub 2012 Nov 19.
Clinical trial NCT00001172: Visual Stimulus and Eye Movement
Official title: Visual Motor Coordination in Man
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Keywords: Vision
Eye Movement
Perception
Healthy Volunteer
Lead sponsor: National Institutes of Health Clinical Center (CC)
Sponsor class: NIH
First posted: 1999-11-04
Enrollment: 225
Sex: ALL
Minimum age (years): 18
Maximum age (years): 59
Standard ages: ADULT
Accepts healthy volunteers: yes

Brief summary: This study is designed to understand how we see visual patterns and how these patterns lead to eye movements.

Normal volunteers participating in this study face a screen on which spots or patterns of light are projected. They are asked to respond to the patterns by voice, eye movements or hand movements. Eye and lid movements are recorded in one of the following ways:

1. Electro-oculogram \< small disc electrodes taped to the skin near each eye measure the eye movements as the eyes change position.
2. Infrared detector \< an infrared beam is reflected off the eye and picked up by detectors that record the eye movements.
3. Contact lens ring \< a smooth plastic ring is placed on the white of the eye surrounding the cornea and eye position is measured using a magnetic coil.

Study sessions last less than four hours.

Detailed description: The purpose of this protocol is to study the physiology of the visuo-motor system in normal humans. This will be accomplished by recording eye movements and other responses (such as reaction time to bar press or verbal responses) to differing stimuli. The stimuli will be primarily visual but may include auditory or tactile stimuli.

Eligibility criteria: * INCLUSION CRITERIA:

Normal adult volunteers age 18 and over are included.

Only normal volunteers are studied under this protocol. Normal volunteers are recruited from the NIH volunteer office and the NIH web page. Women and minorities are actively recruited.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Bethesda
country: United States
facility: National Institutes of Health Clinical Center, 9000 Rockville Pike
state: Maryland
Study officials:
References:
citation: Miles FA. The neural processing of 3-D visual information: evidence from eye movements. Eur J Neurosci. 1998 Mar;10(3):811-22. doi: 10.1046/j.1460-9568.1998.00112.x.
citation: Busettini C, Masson GS, Miles FA. Radial optic flow induces vergence eye movements with ultra-short latencies. Nature. 1997 Dec 4;390(6659):512-5. doi: 10.1038/37359.
citation: Masson GS, Busettini C, Miles FA. Vergence eye movements in response to binocular disparity without depth perception. Nature. 1997 Sep 18;389(6648):283-6. doi: 10.1038/38496.
Clinical trial NCT03981172: Food Reinforcement, Weight Status, and Energy Density
Official title: Effects of Daily Snack Food Intake on Food Reinforcement Depend on Weight Status and Energy Density
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Reinforcing Value of Food
Keywords: food reinforcement
food liking
motivation
dopamine
obesity
energy density
snacks
Lead sponsor: State University of New York at Buffalo
Sponsor class: OTHER
First posted: 2019-06-10
Enrollment: 53
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women ages 18 - 50 were recruited.

Brief summary: The investigators previous studies have shown that obese and non-obese individuals respond differently to daily intake of snack food. The purpose of this study was to determine whether these differences are specific to high energy density snack foods. The investigators hypothesized that obese individuals would show an increase in motivation to obtain high energy density snack foods after two weeks of daily consumption, but that non-obese women and obese women consuming low energy density foods would have reduced motivation to consume snack foods after two weeks of daily consumption.


Eligibility criteria: Inclusion Criteria:

* 18 - 50 years old, female, like study foods.

Exclusion Criteria:

* current smoker, currently on a diet, medical conditions or medication affecting appetite (ex. methylphenidate).

Primary outcomes:
measure: Number of operant responses
timeFrame: about one month
Secondary outcomes:
measure: Food liking
timeFrame: about one month
Other outcomes:
Locations:
city: Buffalo
country: United States
facility: University at Buffalo
state: New York
Study officials:
References:
Clinical trial NCT04733872: Using Vegetable and Berry Products Can Improve Skin Conditions
Official title: Using Vegetable and Berry Products Can Improve Skin Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Skin Condition
Lead sponsor: TCI Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2021-02-02
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hypothesis: vegetable and berry products for 8 weeks can improve skin condition

Detailed description: Hypothesis: Using vegetable and berry products for 8 weeks can improve skin condition

Eligibility criteria: Inclusion Criteria:

1. Dry skin
2. Rough skin
3. Large pores
4. Dark yellow complexion
5. Sagging skin

Exclusion Criteria:

1. Skin disorders
2. Liver diseases
3. Kidney diseases
4. Allergy to cosmetics, drugs, or foods
5. Pregnant and lactating women
6. People who had any cosmetic procedures before 4 weeks of the study
7. Area of facial spot over 3 cm2
8. Vegan
9. People who took collagen supplements in the past 3 months.

Primary outcomes:
measure: skin moisture
timeFrame: up to 8 week
measure: skin elasticity
timeFrame: up to 8 week
measure: skin gloss
timeFrame: up to 8 week
measure: skin spot
timeFrame: up to 8 week
measure: skin wrinkle
timeFrame: up to 8 week
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Research & Design Center, TCI CO., Ltd
state: Neipu Township
Study officials:
affiliation: Chia Nan University of Pharmacy ＆ Science
name: Chia-Hua Liang, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01442272: Value Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D
Official title: Clinical Trial, Open, Parallel Groups , Value the Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Kidney Failure, Chronic
Disorder of Vitamin D
Lead sponsor: Hospital Universitario de Canarias
Sponsor class: OTHER
First posted: 2011-09-28
Enrollment: 174
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the value the additional antiproteinuric effects of vitamin D derivatives treatment, in patients with Chronic Kidney Illness phase II-IV, with lack of vitamin D and residual proteinuria higher 0,5 grams/day.


Eligibility criteria: Inclusion Criteria:

* Male/female Patients older 18 years old
* Patients have signed written informed consent
* Chronic Kidney Illness phase II-IV plus residual proteinuria \>0,5 grams/day (two or more consecutive occasions) and plus beta blockers treatment from AARS during al least 3 months.
* Serum levels of calcifediol in the lack of level (15-30 ng/ml).

Exclusion Criteria:

* Bad control of high blood pressure (higher or same 180/110 mmHg)
* Bad control of diabetes (HbA1c higher 9,5 in the last three months period)
* Hypercalcemia (\<10,2 mg/dL) o hyperphosphatemia(\>5,5 mg/dL), CaxPO4\>50, hypercalciuria (urin Ca/Cr quotient \> 0,15)
* Vitamin D treatment or any analogous
* Hepatic failure ( AST o ALT \> 3 times higher than normal limit)
* medical history of poor nutrient intestinal absorptions or chronic diarrhea
* Active nephrolithiasis
* Treatment with medication wich can change vitamin D metabolism (phenobarbital, phenytoin, rifampicin)
* Participation in other Clinic Trial in 3 last months
* Active Alcoholism
* Neoplasia precedent (except cutaneous no melanoma)
* Pregnant women or while breastfeeding
* Vitamin D hypersensitivity or any its excipient hypersensitivity
* Any other condition from Research

Primary outcomes:
measure: Protein/creatinine quotient and albumin/creatinine in matinal urine sample: basal and 3 period months after a month of the therapeutic protocol beginning.
timeFrame: 1-3 month
Secondary outcomes:
Other outcomes:
Locations:
city: La Laguna
country: Spain
facility: Hospital Universitario de Canarias
state: S/C Tenerife
city: La Laguna
country: Spain
facility: HUC
state: S/c Tenerife
Study officials:
References:
Clinical trial NCT00420472: A Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients Switched From EC-MPS.
Official title: An Open-Label Study to Evaluate the Effect on Quality of Life of Switching Kidney Transplant Patients From Reduced Dose EC-MPS to a Higher Than the Equimolar Dose of CellCept
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Kidney Transplantation
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2007-01-11
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will assess the safety, efficacy and effect on quality of life of switching kidney transplant patients from reduced dose EC-MPS treatment due to gastrointestinal problems to a higher than the equimolar dose of CellCept. Patients will be switched, initially, from EC-MPS (\<1440g/day) to an equimolar dose of CellCept, and at the next visit (day 10 +/- 5) the CellCept dose will be increased by 250mg/day, and the daily dose will be split into 3-4 doses. The anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.


Eligibility criteria: Inclusion Criteria:

* adult patients, \>=18 years of age;
* first or second kidney transplant;
* EC-MPS therapy for \>=6 months, with a stable dose for \>=2 months;
* lower than recommended dose of EC-MPS (\<1440g/day) due to gastrointestinal complaints.

Exclusion Criteria:

* patients who have participated in this study before;
* patients currently participating in another clinical trial, or who participated in one during the last 30 days.

Primary outcomes:
measure: Gastrointestinal Quality of Life index, and Gastrointestinal Symptom Rating Scale, at 3 months.
Secondary outcomes:
measure: Efficacy: Mean dose increase of CellCept. Pharmacokinetics: Comparison of pharmacokinetic parameters under EC-MPS and CellCept therapy. Safety: AEs; acute rejection episodes.
Other outcomes:
Locations:
city: Berlin
country: Germany
city: Berlin
country: Germany
city: Dresden
country: Germany
city: Essen
country: Germany
city: Hannover
country: Germany
city: Köln
country: Germany
city: Münster
country: Germany
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT04520672: Circulating Tumor Cells (CTC) in Cancer
Official title: Circulating Tumor Cells (CTC) in Cancer
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cancer
Keywords: circulating tumor cells (CTCs)
CTC clusters
Molecular analysis of CTCs
CTC culture
overall survival (OS)
progression free survival (PFS)
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2020-08-20
Enrollment: 3000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: adult patients (\> 18 years) with a cancer diagnosis

Brief summary: This observational study with circulating tumor cells (CTC) count, isolation and analysis at several time points during disease progression is to investigate the role and biology of CTCs and clusters of CTCs in different cancer types. It also evaluates the role of CTCs as biomarkers, and aims at the identification of key signaling networks that are active in CTCs.


Eligibility criteria: Inclusion Criteria:

* Adult cancer patients
* All patients with histology-based proved diagnosis of cancer, all stages and subtypes can be included. Precancerous lesions cannot be included.
* All patients with the diagnosis of a solid tumor including adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, sarcoma
* Written pathology report must be available.
* Written informed consent.

Exclusion Criteria:

* No written informed consent.
* No proved diagnosis of malignancy by pathology report.
* Patients with the diagnosis of blood cancer

Primary outcomes:
measure: Overall survival (OS) in heterogeneous cancer population
timeFrame: Screening (Visit 1) until the date of death (assessed up to 240 months)
measure: Change in total number of isolated CTCs
timeFrame: Through study completion, an average of 20 years
Secondary outcomes:
measure: Progression free survival (PFS)
timeFrame: Through study completion, an average of 20 years
Other outcomes:
measure: Change in circulating tumor DNA (ctDNA) from blood samples
timeFrame: Through study completion, an average of 20 years
Locations:
city: Basel
country: Switzerland
facility: University Hospital Basel
city: Liestal
country: Switzerland
facility: Department Oncology, Haematology & Immuntherapy, Kantonsspital Baselland
Study officials:
affiliation: Kantonsspital Baselland, Liestal
name: Marcus Vetter, PD Dr. med.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01148095: To Investigate the Safety, Tolerability and Pharmacokinetics of AZD2516 After Multiple Dosing in Healthy Volunteers
Official title: A Single Centre Two Part Randomized Phase I Study to Assess the Pharmacokinetics of an ER Formulation of AZD2516 and to Assess the Safety, Tolerability and Pharmacokinetics of AZD2516 After Multiple Ascending Doses in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years.
Part B Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 and Elderly Volunteers Aged 60 to 80
Keywords: AZD2516
Phase 1
Healthy volunteer
pharmacokinetics
safety
tolerability
Multiple ascending doses
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
Collaborators: name: Quintiles, Inc.
First posted: 2010-06-22
Enrollment: 6
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: AZD2516 is being developed for the oral treatment of chronic neuropathic pain. This study is split in to two parts. Part A will measure the effect of food and a new formulation of the drug in the blood and see how well it is tolerated. Part B will commence after the completion of Part A and will investigate the safety and tolerability of daily dosing with AZD2516.


Eligibility criteria: Inclusion Criteria:

* Have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg
* Healthy volunteers able and willing to comply with all study requirements.

Exclusion Criteria:

* An ongoing or history of a medical or psychiatric disease/condition which may put the healthy volunteer at risk or interfere with the study objectives because of participation in the study, as judged by the investigator(s).
* History of psychotic disorder among first degree relatives.

Primary outcomes:
measure: Adverse Events, vital signs
timeFrame: Day -1 until follow-up
Secondary outcomes:
measure: Maximum plasma concentration (Cmax)
timeFrame: Day 1 - Day 12
measure: Time to Cmax (tmax)
timeFrame: Day 1 - Day 12
measure: Terminal rate constant (λz)
timeFrame: Day 1 - Day 12
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Research Site
Study officials:
affiliation: Quintiles Drug Research Unit 6, Newcomen Street, London, SE1 1YR
name: Darren Wilbraham, MBBS, DCPSA
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02958995: Epidemiologic Study Of Diabetes And Cancer Risk
Official title: Epidemiologic Study Of Diabetes And Cancer Risk
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes Mellitus, Type 2, Cancer
Keywords: Drug Therapy
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2016-11-08
Enrollment: 2738161
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Participants with a historical diagnosis of Type 2 diabetes mellitus (T2DM) with pioglitazone exposure identified from the Kaiser Permanente of Northern California(KPNC) Diabetes Registry (with or without diabetes) and had completed Member Health Survey (MHS) were enrolled in the epidemiology study.

Brief summary: The purpose of this study was to evaluate whether treatment with pioglitazone is associated with risk of incident cancer at the 10 most common sites in a cohort of participants with recognized diabetes along with the assessment of association between diabetes severity and cancer risk.

Detailed description: The study enroll a large population of approximately 252467 participants. This epidemiology study of diabetes and cancer risk is an expansion study which would include estimation of cancer rate among KPNC members with or without diabetes and the relative risks of cancers associated with a diagnosis of diabetes. The study included diabetes participants who were KPNC members between 1997 and 2011. It also included a subset of participants who took the 1996/7 diabetes survey and Member Health Survey (MHS) in 1993, 1999, 2001 or 2003.

This multi-center trial was conducted in the United States of America. The overall time to participate in this study was approximately 15.5 years. The participants were followed-up from January 1, 1997 up to December 31, 2011.

Eligibility criteria: Inclusion Criteria: 1. has been in the KPNC diabetes registry Diabetes Mellitus (DM) registry, aged 40 years or older and are members of KPNC as of January 1, 1997 and had no prior diagnosis of the cancer of interest.

Primary outcomes:
measure: Age and Sex-Standardized Incidence Rates for the 10 Most Common Cancers Stratified by Diabetes Status
timeFrame: 15 years
measure: Hazard Ratio for Risk of 10 Common Cancers Associated With Diabetes
timeFrame: 15 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Takeda
name: Medical Director
role: STUDY_DIRECTOR
References: